



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)  
from Capital District Health Authority/Cancer Care Nova Scotia**

**Guidelines for the Role of Nilotinib in Chronic Myelogenous Leukemia (CML)**

**Approved Use:**

**Nilotinib:** As a **single second line agent** for the treatment of adults with chronic or accelerated phase CML with resistance or intolerance to prior therapy.

These criteria include:

1. Patients with CML in chronic phase who are intolerant to imatinib or dasatinib or both.
2. Patients with CML in chronic phase who are resistant to imatinib 600 mg/day.
3. Patients with CML that have progressed to accelerated phase while on imatinib therapy.

Sequential use of dasatinib and nilotinib is **not** permitted except in the circumstance described above (i.e. intolerance).

Approved by: \_\_\_\_\_

Date: \_\_\_\_\_